Article
Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.
Leukemia - 1 Aug 2026
Lee Darren, Abu-Shihab Yazan, Plas Kate, Nicolet Deedra, Mrózek Krzysztof, Routbort Mark J, Patel Keyur P, Walker Christopher J, Buss Jill, Stiff Andrew R, Laganson Andrea, DiNardo Courtney D, Daver Naval G, Kadia Tapan M, Ravandi Farhad, Carroll Andrew J, Kolitz Jonathan E, Powell Bayard L, Blum William G, Baer Maria R, Marcucci Guido, Uy Geoffrey L, Stock Wendy, Stone Richard M, Medeiros L Jeffrey, Byrd John C, Blachly James S, Bowman Robert L, Tyner Jeffrey W, Loghavi Sanam, Eisfeld Ann-Kathrin, Miles Linde A
Abstract excerpt
Mutations in the RAS/MAPK signaling pathway are recurrent in acute myeloid leukemia (AML), primarily involving NRAS and KRAS. In contrast, mutations in the gene encoding an effector protein, BRAF, occur at relatively lower frequencies in AML and are associated with poor outcomes. To date, no comprehensive analysis has assessed the clinical and molecular characteristics of BRAF-mutated AML. In this study, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.